Male Breast Carcinoma Completed Phase 1 / 2 Trials for Cixutumumab (DB12250)

IndicationStatusPhase
DBCOND0030384 (Male Breast Carcinoma)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00699491Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerTreatment